Disc Medicine, Inc. (NASDAQ:IRON) Stock Holdings Increased by Victory Capital Management Inc.

Victory Capital Management Inc. lifted its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 46.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 312,049 shares of the company’s stock after purchasing an additional 98,988 shares during the quarter. Victory Capital Management Inc.’s holdings in Disc Medicine were worth $14,064,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its stake in Disc Medicine by 59.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock valued at $58,788,000 after purchasing an additional 353,382 shares in the last quarter. Jennison Associates LLC lifted its holdings in Disc Medicine by 349.1% in the 1st quarter. Jennison Associates LLC now owns 193,240 shares of the company’s stock valued at $12,031,000 after acquiring an additional 150,209 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Disc Medicine by 19.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 785,000 shares of the company’s stock valued at $45,342,000 after purchasing an additional 130,000 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of Disc Medicine by 14.2% in the 4th quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock worth $59,091,000 after purchasing an additional 127,404 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Disc Medicine by 224.6% in the 4th quarter. Wellington Management Group LLP now owns 177,726 shares of the company’s stock worth $10,265,000 after purchasing an additional 122,981 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IRON. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Disc Medicine in a report on Friday, August 9th. Wells Fargo & Company began coverage on Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $70.00 price target (up previously from $50.00) on shares of Disc Medicine in a research report on Monday, June 17th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Disc Medicine in a report on Wednesday, July 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, May 28th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $64.13.

Disc Medicine Stock Down 1.0 %

IRON stock opened at $47.79 on Friday. The company has a 50 day moving average of $46.95 and a two-hundred day moving average of $44.08. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -14.14 and a beta of 0.59. Disc Medicine, Inc. has a 12-month low of $25.60 and a 12-month high of $77.60.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.08. On average, research analysts anticipate that Disc Medicine, Inc. will post -4.19 EPS for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.